Ultragenyx Reports Third Quarter 2026 Financial Results, Announces Substantial Expense Reductions, and Reaffirms Profitability in 2027
Globe Newswire•03/11/2026•16:01 ET
0
Key Highlights
- ➤Q3 revenue $173 million, up from $160 million year over year
- ➤2026 revenue guidance reaffirmed at $730 million to $760 million
- ➤PRV agreements total $413 million, with approximately $350 million net proceeds expected
- ➤2027 R&D expenses targeted below $350 million after approximately 20% headcount reduction
- ➤Ultragenyx expects full-year GAAP profitability in 2027 and thereafter
Expert Statements
Emil D. Kakkis, Chief executive officer and president of Ultragenyx
“We received two BLA approvals from the FDA within one month for our first gene therapy treatments and the launches are progressing well with growing demand for these products”
Emil D. Kakkis, Chief executive officer and president of Ultragenyx
“With substantial reductions in headcount and expenses, combined with two launches and continued growth in our base business, we expect meaningful profitability in 2027 and going forward.”
Third quarter total revenue of $173 million, CRYSVITA® revenue of $109 million and DOJOLVI® revenue of $30 million
GENGLYCOS™ and FAYUVI™ BLAs approved by FDA in the third quarter
Get started
Create a free account to read the full story.